



CLIENT OBJECTIVES ▾

PRACTICE MANAGEMENT ▾

TREATMENT SOLUTIONS ▾





Post-Surgical Vests
+ Compression Garments
100% Made in USA
affirmawear.com



PULSE BIOSCIENCES PRESENTS CLINICAL RESULTS AT ASDS VIRTUAL ANNUAL MEETING

Posted by Debbie Overman | Oct 12, 2020 | company news,
Dermatology, News, Research | 0 🗨️ | ★★★★★



FOLLOW US

f Facebook

🐦 Twitter

in LinkedIn

[Pulse Biosciences Inc](#) presented clinical results from studies spanning the Company's dermatologic application portfolio recently at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting, held October 9-11, 2020.

Positive study results generated using the Company's innovative cellular-specific Nano-Pulse Stimulation mechanism performed with its CellFX System for the treatment of sebaceous hyperplasia lesions, cutaneous non-genital warts, plantar warts, and basal cell carcinoma will be presented in two oral presentations and two e-posters.

These newest published results from NPS clinical studies provide further evidence of the unique CellFX cellular mechanism of action for multiple applications across the lesion treatment spectrum, according to the company in a media release.

These recent findings were also the basis for the recently initiated multicenter clinical study to compare NPS technology to RF electrodesiccation in clearing sebaceous hyperplasia lesions.

“The positive results being shared at this year’s ASDS meeting add to the growing body of evidence in support of using Nano-Pulse Stimulation technology delivered by the CellFX System to treat a broad range of dermatology applications for which targeted clearance of cellular lesions or structures is medically or cosmetically desirable.

“These data underscore our persistent dedication to providing dermatologists a highly differentiated non-thermal solution with vast opportunity.”

— Darrin Uecker, President and CEO of Pulse Biosciences

MEETING HIGHLIGHTS

Highlights from this meeting of leading dermatologic surgeons demonstrate:

- Successful use of lower NPS energy levels to maintain high levels of effectiveness in clearing sebaceous hyperplasia lesions with greatly improved cosmesis and high subject satisfaction
- Favorable clearance rate for warts on the hands, leg, knee, neck; no plume detected in a subset of NPS procedures
- Encouraging findings of biopsy-confirmed elimination of residual BCC in the known NPS treatment zone for 8 nodular BCCs and 21 superficial BCCs, indicating promising potential for NPS treatment of both BCC-subtypes
- Strong clearance rate of difficult-to-treat, recalcitrant plantar warts in a single treatment session

“We are pleased to present conclusive evidence of consistently high rates of clearance across a variety of

anatomical areas in one to two NPS treatments. Compared to today's standard wart treatments, which typically require two to four visits to clear common cutaneous warts, these NPS results represent a much more convenient approach for the patient and the physician."

— Dr. Ted Lain, Chief Medical Officer of Sanova Dermatology in Austin, Tex, and author of the non-genital cutaneous wart study

Members of the dermatologic surgery community who have registered for the virtual meeting can gain access to accepted video presentations and posters at the [ASDS meeting portal](#).

[Source(s): Pulse Biosciences Inc, Business Wire]

Related Content:

[Nano-Pulse Stimulation Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 ASLMS Virtual Annual Conference](#)

SHARE:



RATE:



< PREVIOUS

NEXT >

[Could Cosmetic Surgery Be Right for You? Find Out with These Tips](#)

[Revance Presents DaxibotulinumtoxinA for Injection and RHA Collection Data at the ASDS Virtual Annual Meeting](#)

ABOUT THE AUTHOR



Debbie Overman

RELATED POSTS




Total Abdominal Wall Transplantation for Complex Transplant Cases—Experts Outline Technique

May 30, 2017



Method Developed to Minimize Damage On Sural Artery Perforator Flap Surgery

November 28, 2017



Cohera Medical Gets FDA OK to Start Tissue Glue Tummy Tuck Trial in the US

January 24, 2012



Soliton To Announce Results of Pivotal Cellulite Clinical Trial at AAD Virtual Meeting

June 9, 2020

LEAVE A REPLY

Your email address will not be published. Required fields are marked *

COMMENT

NAME *

EMAIL *

WEBSITE

Save my name, email, and website in this browser for the next time I comment.

POST COMMENT

SEARCH ...

MEDQOR MEDIA TITLES

RESOURCES

24x7

Podcasts

FOLLOW US

Axis Imaging News

Videos

Clinical Lab Products

Webinars

The Hearing Review

White Papers

 Facebook

Orthodontic Products

Physical Therapy Products

Rehab Management

RT: For Decision Makers in Respiratory Care

Sleep Review

HELPFUL LINKS

Media Kit

Subscribe

Contact Us